东北固收转债分析：金威转债定价：首日转股溢价率33-36%

1. Report Industry Investment Rating No relevant content provided. 2. Core Viewpoints of the Report - On August 18, 2025, Jindawei announced plans to issue convertible bonds worth up to 1.292 billion yuan on August 20, 2025, through online distribution. The funds will be used for projects such as the Coenzyme Q10 Reconstruction and Expansion Project, the Annual Production of 30,000 Tons of Allulose and 5,000 Tons of Inositol Construction Project, the Information System Construction Project, and to supplement working capital [1][12]. - The initial conversion price of Jinwei Convertible Bond is 19.59 yuan. As of August 19, 2025, the bond's parity is 99.95 yuan, and the estimated conversion premium rate on the first - day of listing is in the range of 33% - 36%, with a target price of 133 - 136 yuan. It is recommended to actively subscribe [2][19]. - The estimated first - day new bond subscription winning rate is around 0.0061% - 0.0072% [20]. 3. Summary According to the Directory 3.1. Jinwei Convertible Bond New Bond Analysis and Investment Recommendations 3.1.1. Analysis of Convertible Bond Basic Terms - The issuance methods of Jinwei Convertible Bond are priority placement and online distribution, with a debt and issuer rating of AA. The issuance scale is 1.292 billion yuan, the initial conversion price is 19.59 yuan, the bond parity is 99.95 yuan, and the pure bond value is 98.2 yuan. The game terms are normal, with high issuance scale, good liquidity, acceptable rating, and good bond floor protection. It is easy for institutions to include it in their portfolios, and there is no objection to primary participation [2][14]. 3.1.2. Analysis of New Bond Initial Listing Price - The company mainly engages in the R & D, production, and sales of nutritional health foods (including raw materials and end - products) and feed additives. The funds raised from this issuance will be used for specific projects, which are in line with industry trends, can enhance the company's market competitiveness, optimize its capital structure, and support its development [18]. - The target price of the convertible bond on the first day of listing is 133 - 136 yuan, and it is recommended to actively subscribe. Considering the market environment and parity level, the estimated conversion premium rate on the first - day of listing is in the range of 33% - 36% [2][19]. 3.1.3. Analysis of Convertible Bond New Bond Subscription Winning Rate - As of the end of 2024, the top two shareholders held 53.39% of the shares, and the top ten shareholders held 60.76%. Assuming the old shareholders' placement ratio is 53% - 61%, the scale available for the market is 507 million - 602 million yuan. Referring to recent bond issuances, the estimated winning rate is around 0.0061% - 0.0072% [20]. 3.2. Analysis of the Underlying Stock's Fundamental Situation 3.2.1. Company's Main Business and Industry Upstream and Downstream - The company is mainly involved in the R & D, production, and sales of nutritional health foods and feed additives. The upstream of the nutritional health food industry includes raw material producers, and the downstream includes brand operators and channel merchants. The upstream of the feed additive industry consists of raw material - providing industries, and the downstream is the feed manufacturing industry. Various factors such as raw material price fluctuations, industry development, and market competition affect the industry [21][22]. 3.2.2. Company's Operating Conditions - From 2022 to Q1 2025, the company's operating income showed an increasing trend, with year - on - year growth rates of - 16.78%, 3.1%, 4.43%, and 11.31% respectively. The company's comprehensive gross profit margin fluctuated slightly, and the net profit margin increased. The company's accounts receivable showed an upward trend, and the turnover rate fluctuated. The net profit attributable to the parent company began to grow [25][35][38]. 3.2.3. Company's Equity Structure and Major Subsidiaries - As of the end of 2024, the company's equity structure was relatively concentrated. The top two shareholders held 53.39% of the shares, and the top ten shareholders held 60.76%. The Wang family indirectly controlled 60.18% of the shares and was the actual controller. The company had 28 holding companies and 8 participating companies [42]. 3.2.4. Company's Business Characteristics and Advantages - The company has advantages in technological innovation, overseas operations, large - scale production, personnel reserves, and patents. It has multiple R & D platforms, overseas subsidiaries, rich production experience, a professional talent team, and 194 patents as of December 31, 2024 [44][47][48]. 3.2.5. Arrangement of This Fund - Raising Investment - The company plans to raise up to 1.292 billion yuan. The Coenzyme Q10 Reconstruction and Expansion Project, with a total investment of 320 million yuan and a planned use of 297 million yuan of the raised funds, aims to increase production capacity. The Annual Production of 30,000 Tons of Allulose and 5,000 Tons of Inositol Construction Project, with a total investment of 537 million yuan and a planned use of 464 million yuan of the raised funds, will supplement product categories. The Information System Construction Project, with a total investment of 153 million yuan and a planned use of 144 million yuan of the raised funds, will improve the company's informatization level [49][50][51].